跳至主要内容
临床试验/IRCT20230809059099N2
IRCT20230809059099N2招募中Unknown

Efficacy and safety of the Defibrillator / Monitor model Re-pulse6 Avecinna Co. among patients with atrial fibrillation and flutter who are candidates of elective cardioversion: a stratified non-inferiority randomized controlled trial at Tehran Heart Center

Avecinna co0 个研究点目标入组 105 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
105

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 90 years(—)
性别
All

入选标准

  • Age >18 years old
  • Atrial fibrillation or flutter
  • indication for cardioversion
  • Atrial fibrillation or flutter will be confirmed by an electrophysiologist using 12 lead standard ECG. Cardioversion will be conducted at the discretion of the electrophysiologist.
  • All patients are required to receive at least 4 weeks of antio coagulation or left atrial thrombus is ruled out by trans esophageal echocardiography

排除标准

  • Requiring emergeny cardioversion
  • Hemodynamic instability
  • Chest pain or suspicion of acute coronary syndrome
  • Hypokalemia
  • Digoxin toxicity
  • Pregnancy or breastfeeding
  • No informed consent

研究者

发起方
Avecinna co

相似试验